학술논문
Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755